Edgewise Therapeutics, Inc. (EWTX)
EWTXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$48.00
+2.22 (+4.85%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $5.34bn
- P/E
- –
- EPS, last 4 quarters
- $-0.6200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $16.70 to $48.51
- Average volume
- 1.56m
- Previous close
- $45.78
Analysts
12 coveringBuy10 buy, 2 hold, 0 sell
Targets a year out average $54.30, +13.1% from here
Earnings
next estimate $-0.4900Next report
Dec 2025
-9.3%
Mar 2026
+8.0%
Jun 2026
-10.4%
Sep 2026
+252.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$55.98m | -$54.12m | -$61.94m | -$46.14m |
| Net income | -$50.22m | -$49.01m | -$57.33m | $1.17bn |
News
8 latest- Edgewise Therapeutics Reports Third Quarter 2026 Financial Results and $1.348 billion Gain on Sevasemten SaleFintel · 5 days ago
- Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Zacks · Oct 19, 2026
- Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down RTTNews · Oct 8, 2026
- Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Zacks · Oct 2, 2026
- Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? Zacks · Sep 4, 2026
- Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?Zacks · Sep 2, 2026
- Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?Zacks · Aug 27, 2026
- Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?Zacks · Jul 17, 2026
The company
Edgewise Therapeutics is a cardiovascular biopharmaceutical company developing novel therapies intended to address cardiac equilibrium, the balance of contraction and relaxation across the cardiac cycle. Drawing on deep expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing novel therapies intended to fine-tune cardiac muscle function and improve treatment options for people with symptomatic hypertrophic cardiomyopathy and heart failure.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- edgewisetx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.